Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

FDA approves Alnylam’s anti-amyloid RNAi drug for cardiomyopathy

FDA approves Alnylam’s anti-amyloid RNAi drug for cardiomyopathy News the drug do to your brain,” says Güler. They Relapse is a significant problem in any form News in brief reported that danuglipron directly engages of addiction, and rates remain stubbornly high neurons in the central amygdala, a region even when patients are receiving drug thera- FDA approves outside the circumventricular organs. The pies, such as methadone, buprenorphine or team further identified a previously unknown naltrexone for opioid use disorder and acam- Alnylam’s dopamine-regulated neural circuit regulating prosate, disulfiram or naltrexone for alcohol hedonic or pleasure-seeking eating, which is use disorder. It is not yet clear whether GLP-1 anti-amyloid distinct from the circuits controlling regu- receptor agonists will face the same prob- lar food intake. Both danuglipron and orfor- lem if approved for addiction indications. RNAi drug for glipron dampened this activity, in addition “We’re definitely going to have to see,” says to normal feeding, further underlining their Patricia ‘Sue’ Grigson-Kennedy, who chairs cardiomyopathy potential as addiction therapies. But Güler Penn State’s Department of Neuroscience and cautions that more research is needed on Experimental Therapeutics. “If we titrate up he first RNA interference (RNAi) drug for understanding the full spectrum of GLP-1 to a fairly high dose, we http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Biotechnology Springer Journals

FDA approves Alnylam’s anti-amyloid RNAi drug for cardiomyopathy

Nature Biotechnology , Volume 43 (4) – Apr 1, 2025
Download PDF
1 page

FDA approves Alnylam’s anti-amyloid RNAi drug for cardiomyopathy

Abstract

News the drug do to your brain,” says Güler. They Relapse is a significant problem in any form News in brief reported that danuglipron directly engages of addiction, and rates remain stubbornly high neurons in the central amygdala, a region even when patients are receiving drug thera- FDA approves outside the circumventricular organs. The pies, such as methadone, buprenorphine or team further identified a previously unknown naltrexone for opioid use disorder and acam-...
Loading next page...
 
/lp/springer-journals/fda-approves-alnylam-s-anti-amyloid-rnai-drug-for-cardiomyopathy-xYP0r5IEeU

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Nature America, Inc. 2025
ISSN
1087-0156
eISSN
1546-1696
DOI
10.1038/s41587-025-02656-2
Publisher site
See Article on Publisher Site

Abstract

News the drug do to your brain,” says Güler. They Relapse is a significant problem in any form News in brief reported that danuglipron directly engages of addiction, and rates remain stubbornly high neurons in the central amygdala, a region even when patients are receiving drug thera- FDA approves outside the circumventricular organs. The pies, such as methadone, buprenorphine or team further identified a previously unknown naltrexone for opioid use disorder and acam- Alnylam’s dopamine-regulated neural circuit regulating prosate, disulfiram or naltrexone for alcohol hedonic or pleasure-seeking eating, which is use disorder. It is not yet clear whether GLP-1 anti-amyloid distinct from the circuits controlling regu- receptor agonists will face the same prob- lar food intake. Both danuglipron and orfor- lem if approved for addiction indications. RNAi drug for glipron dampened this activity, in addition “We’re definitely going to have to see,” says to normal feeding, further underlining their Patricia ‘Sue’ Grigson-Kennedy, who chairs cardiomyopathy potential as addiction therapies. But Güler Penn State’s Department of Neuroscience and cautions that more research is needed on Experimental Therapeutics. “If we titrate up he first RNA interference (RNAi) drug for understanding the full spectrum of GLP-1 to a fairly high dose, we

Journal

Nature Biotechnology – Springer Journals

Published: Apr 1, 2025

There are no references for this article.